Co-Delivery Nanosystems for Cancer Treatment: A Review.
Anti-cancer materials
cancer therapy
co-delivery
drug-drug
drug-gene
gene-gene
therapeutic
agents.
Journal
Pharmaceutical nanotechnology
ISSN: 2211-7393
Titre abrégé: Pharm Nanotechnol
Pays: United Arab Emirates
ID NLM: 101623431
Informations de publication
Date de publication:
2019
2019
Historique:
received:
19
11
2018
revised:
08
01
2019
accepted:
18
03
2019
pubmed:
26
3
2019
medline:
4
12
2019
entrez:
26
3
2019
Statut:
ppublish
Résumé
Massive data available on cancer therapy more than ever lead our mind to the general concept that there is no perfect treatment for cancer. Indeed, the biological complexity of this disease is too excessive to be treated by a single therapeutic approach. Current delivery systems containing a specific drug or gene have their particular opportunities and restrictions. It is worth noting that a considerable number of studies suggest that single- drug delivery systems result in insufficient suppression of cancer growth. Therefore, one of the main ideas of co-delivery system designing is to enhance the intended response or to achieve the synergistic/combined effect compared to the single drug strategy. This review focuses on various strategies for co-delivery of therapeutic agents in the treatment of cancer. The primary approaches within the script are categorized into co-delivery of conventional chemotherapeutics, gene-based molecules, and plant-derived materials. Each one is explained in examples with the recent researches. In the end, a brief summary is provided to conclude the gist of the review.
Identifiants
pubmed: 30907329
pii: PNT-EPUB-97485
doi: 10.2174/2211738507666190321112237
doi:
Substances chimiques
Antineoplastic Agents
0
Nanocapsules
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
90-112Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.